SEC Form 4 · accession 0000911916-15-000186
CoLucid Pharmaceuticals, Inc. · CLCD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
May 11, 2015
Accepted (ET)
May 12, 2015 · 5:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 11, 2015 | C | 995,386 | — | A | 995,386 | I | By TVM Life Science Ventures VII L.P. |
| Common StockF2 | May 11, 2015 | P | 500,000 | $10.00 | A | 1,495,386 | I | By TVM Life Science Ventures VII L.P. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C Convertible Preferred StockF2,F1,F3 | — | May 11, 2015 | C | 995,386 | D | — | — | Common Stock | 995,386 | 0 | I |
Explanation of responses
- F1Each share of Series C Convertible Preferred Stock was convertible at any time at the option of the holder, and converted automatically into shares of the Issuer's Common Stock on a one-for-one basis in connection with the closing of the Issuer's initial public offering.
- F2Represents securities held directly by TVM Life Science Ventures VII L.P. TVM Life Science Ventures VII (GP) Ltd. is the general partner of TVM Life Science Ventures VII L.P. The reporting person is a managing partner of the investment team of TVM Life Science Venture Capital, which has voting and investment power with respect to these shares. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- F3The securities did not have an expiration date. The securities converted automatically into shares of the Issuer's Common Stock on a one-for-one basis in connection with the closing of the Issuer's initial public offering.